Ahithophel Weissberger

Mannkind: Overlooked Biotech With Excellent Prospects (Part III)

Ballhawker:
I think that my last comment (the one right before yours) addressed those issues quite directly. I don't believe that it will EVER be available in the U.S. market, certainly not the way their clinical trials have been conducted up till now. If we would hypothesize someone buying Generex and starting the clinical trials from scratch, they would basically have to start from the beginning of Phase II, which would put them at at least 5 years away from market, assuming that all the trial results showed effectiveness and safety. I wish I could give you more data on the results from Oral-lyn's clinical trials, but I can't know more than Generex will release. It really is immaterial because as things stand now, Oral-lyn will never be approved, neither in the U.S. nor in Europe. If Generex raised more money or if someone would buy it from them and conduct fresh clinical trials of proper size and length, they would still be at least 5 years away from market, as I said before. Read my last comment for more details.